Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial

Peer Review reports

Original Submission
9 Dec 2020	Submitted	Original manuscript
17 Jan 2021	Reviewed	Reviewer Report - Riaz Qureshi
22 Jan 2021	Reviewed	Reviewer Report - LAURA RICHERT
7 Mar 2021	Author responded	Author comments - Adam G Stewart
Resubmission - Version 2
7 Mar 2021	Submitted	Manuscript version 2
16 Mar 2021	Reviewed	Reviewer Report - LAURA RICHERT
17 Mar 2021	Reviewed	Reviewer Report - Riaz Qureshi
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
18 Mar 2021	Editorially accepted
22 Apr 2021	Article published	10.1186/s13063-021-05206-8

Back to article page